Abstract 1871
Background
Much of the work of a busy oncology day unit is undocumented, especially the work involved in phone triage during the working hours of 8am to 6pm. Phone calls from patients, their family doctors, palliative care teams, or from within the Hospital itself seeking advice form the majority of this aspect of the Specialist Oncology Nurse and Staff Nurses’ time. This project was performed to assess the nature of these calls and the broad advice given to the callers so that a dedicated Acute Review Specialist Oncology Nurse Clinic could be developed.
Methods
In conjunction with key oncology nurses and their medical oncologist colleagues a log to capture each answered call was developed. This centred on the date and time of the call, the source, the issue raised, the advice given, if advised to go to the Emergency Room the reason why, and other actions that were necessary. A form was completed per answered call, and collected at the end of the day. Data was recorded on a spreadsheet. All forms were annonymised with regard to patient identifiers. The forms were focused on whether the issue was successfully addressed within the day unit, the Hospital’s emergency room, the community services, or whether solely by the advice given over the telephone.
Results
A sample size of 252 incoming answered calls by the Oncology Nursing Staff to the Nurses’ station was analysed. Just over half these calls (52%) were made by patients/family members. Other calls related to internal questions such as from Interventional Radiology or other diagnostic areas of the Hospital (26%), pharmacies (7%), and family doctors (4%). The other 11% of calls were mainly from wards relating to advice on inpatients or seeking consults. Of the unwell patients calling for advice, near half (48%) were seeking advice on what action to take: stay at home or come to Hospital. 35% of patients were seeking either a new appointment or change in appointment date. The remaining 17% of patients were seeking non-emergency review by the medical oncology team.
Conclusions
This analysis of answered calls highlights the need for involvement of experienced oncology nurses in the triage of phone calls to a busy oncology day unit, and the need to develop an Acute Review Clinic, managed by an experienced oncology nurse specialist.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beaumont Hospital Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract